1. Introduction {#sec0005}
===============

With the goal of establishing guidelines for good practice in *in-silico* research into traditional Chinese medicines (TCM), the WP4 working party of the FP7-funded European consortium for GP-TCM (*Good Practice in Traditional Chinese Medicine Research in the Post-genomic Era*) ([@bib0405]) deemed it appropriate first of all to draw up a catalogue of the various resources currently available, and then to review the use of such resources in the *in-silico* TCM research reported in the literature to date. The computing resources considered included the various databases currently available and the software that has been or might be used in analyses of these data. The various different kinds of databases identified as relevant included those holding ethnobotanical and/or chemical and/or pharmacological and/or toxicological data on the herbs used in Chinese medicine, as well as those that hold data on known or potential molecular targets for the herbal constituents. The software tools considered as relevant included programs that provide for (a) virtual screening of natural product libraries and chemical libraries, (b) pattern recognition, (c) bioinformatics studies relating to TCM and (d) the various data visualisation and statistical analysis packages for proteomics/genomics/metabolomics studies involving TCM.

2. Terminology and communication problems between specialist and non specialist {#sec0010}
===============================================================================

Preliminary discussions of the *in-silico* WP4 working party focussed on the problems of terminology, and the difficulties associated with performing scientifically sound and fruitful *in-silico* studies in Chinese herbal medicines (CHM) research. For the purposes of the review, *in-silico* studies were defined as those involving virtual screening and/or cheminformatics, but more widely would also include those involving bioinformatics and the various different types of 'omics' studies. The view was universally held that any such studies could not be fruitfully performed by non-specialists -- even though the software tools were often easily accessed and easily used by those unfamiliar with computational chemistry. It was unanimously accepted that the performance of *in-silico* studies in CHM research necessitated close interaction between computational chemists and CHM experimentalists. Such interaction is common in the cross-disciplinary areas of molecular pharmacology and structural biology, and *in-silico* CHM research would thus present no exception.

3. Catalogue of existing databases {#sec0015}
==================================

It is vitally important to any *in-silico* studies of CHM that the associated phytochemical data are available in a format suitable for virtual screening (VS) or other informatics applications. Over recent years the information available for Chinese herbs has increased quite dramatically, and the phytochemical classes found within individual plants are often characterised by a large variety of closely related constituents, many of which have been investigated in detail over the past few decades. A catalogue of the databases currently available and relevant to computational studies of CHM is presented in [Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"} . The databases listed include those holding (a) botanical information on TCM herbs, and the composition of TCM formulae and their usage, (b) information on the phytochemical constituents of plants (including those used in TCM and others), and (c) information on known and potential protein targets of the phytochemical constituents of herbs used in TCM. The databases containing category (a) and/or category (b) data are shown in [Table 1](#tbl0005){ref-type="table"}; those containing data in category (c) are shown in [Table 2](#tbl0010){ref-type="table"}.Table 1Catalogue of databases holding botanical information on TCM herbs and/or the composition of TCM formulae and their usage and/or information on the phytochemical constituents of plants (including those used in CHM).DatabaseContentSourceURL**TCM and chemical structure data**TCM Database\@TaiwanChinese medicine database that contains 3-D structural information of TCM constituents -- ready for molecular docking simulation (database currently holds 37,170 (32,364 non-duplicate) TCM compounds from 352 TCM)[@bib0035][http://tcm.cmu.edu.tw/review.php?menuid=3](http://tcm.cmu.edu.tw/review.php%3Fmenuid=3)China Natural Products Database (CNPD)Information on Chinese natural products including \>40,000 structures. Full set of structures[@bib0290][http://www.neotrident.com](http://www.neotrident.com/)3D Structure Database of Components from Chinese Herbs3D structures (\>10,000) from Chinese herbs (\>2000), with descriptors and data on clinical uses. Full set of structures[@bib0255]--Comprehensive Herbal Medicine Information System for Cancer (CHMIS-C)Integrated information on cancer molecular targets, Chinese herbal recipes and phytochemical constituents. Some structures[@bib0115]<http://sw16.im.med.umich.edu/chmis-c/>Chinese herbal constituents database (CHCD) and Bioactive plant compounds Database (BPCD)Information and structures for \>13,000 constituents of ≈300 commonly used herbs. \>2500 compounds active against ≈80 targets. Full set of structures[@bib0095], [@bib0100]<http://www.chemtcm.com/>Ethnopharmacological Database (GPNDB™)100,000 natural products (3D structures), biological activities, ethnopharmacological data. In-house database of Greenpharma S.A.[@bib0085][http://www.greenpharma.com](http://www.greenpharma.com/)Traditional Chinese Medicine Information Database (TCM-ID)Information on 1197 formulas, 1098 herbs and 9852 constituents in relation to TCM diagnosis and prescription. Some structures[@bib0045]<http://tcm.cz3.nus.edu.sg/group/tcm-id/tcmid.asp>**TCM data only**Dictionary of Chinese HerbsTCM herbal formulas, specificity, toxicity and side effects. No structures--[http://Alternativehealing.org/Chinese_herbs_dictionary.htm](http://alternativehealing.org/Chinese_herbs_dictionary.htm)Traditional Chinese Medicine Database SystemBibliographic database (TCMLARS), and Chinese herb database (TCDBASE) in addition to other data--[http://www.cintcm.com](http://www.cintcm.com/)TCMGeneDITInformation on relations between TCM and gene regulation, protein-protein interactions and biological pathways[@bib0120]<http://tcm.lifescience.ntu.edu.tw/>TCM Knowledge Based GridTCM herb database, literature database, traditional Tibetan herb database. No structures--[http://www.cintcm.com](http://www.cintcm.com/)TCM AssistantTCM herbs, herbal formulas, diseases and patent prescriptions. No structures--[http://www.tcmassistant.com](http://www.tcmassistant.com/)**Phytochemical data only**PhytochemDBChemical composition of 1278 taxa (\>19,000 constituents), including Chinese herbs. No structures--<http://ukcrop.net/perl/ace/search/PhytochemDB>Dr. Duke\'s Phytochemical and Ethnobotanical DatabasesInformation on phytochemicals from \>1000 plants, including Chinese herbs. No structures[@bib0090]<http://www.ars-grin.gov/duke/>Dictionary of Natural Products (DNP)Major source of chemical information on natural products, including some biological sources, and pharmacological and toxicological data. Full set of structures--[http://dnp.chemnetbase.com](http://dnp.chemnetbase.com/)Table 2A catalogue of databases holding information on the structures of known and potential protein targets of the phytochemical constituents of herbs used in TCM.DatabaseContentSourceURLTherapeutic Target Database (TTD)Information on 1894 targets, 5028 drugs, diseases, and pathways[@bib0390]<http://xin.cz3.nus.edu.sg/group/ttd/ttd.asp>Potential Drug Target Database (PDTD)Information on 830 targets, protein and active site structures, biological functions, diseases and pathways[@bib0150]<http://www.dddc.ac.cn/pdtd/>Protein Data BankInformation of 70,000+ protein structures determined by single crystal X-ray diffraction or high filed ^1^H NMR studies[@bib0015]<http://www.rcsb.org/pdb>

Of the TCM and natural product databases that have been constructed that provide information relevant to *in-silico* studies of CHM ([Table 1](#tbl0005){ref-type="table"}), the majority (ten out of the total of fifteen) appear to contain either limited or no chemical data on the phytochemical constituents of the herbs, and would clearly, therefore, have limited utility in any bioinformatics/cheminformatics research.

As regards the protein/target databases holding information relevant to *in-silico* CHM studies ([Table 2](#tbl0010){ref-type="table"}), the principle resource -- since it contains details of *all* publicly available protein 3D structures -- is provided by the Protein Data Bank (PDB; [@bib0015]). The Therapeutic Target Database (TTD; [@bib0390]) and the Potential Drug Target Database (PDTD; [@bib0150]) are more focused resources, providing details of proteins of specific interest in development of new drug therapies and/or studies of mechanisms of drug/CHM phytochemical action.

In assessing the utility of the various databases available, the following considerations were made:•The availability of a database is important to consider, and although sources which are not publicly available are unlikely to be of interest to most people, such databases might nevertheless be of interest to researchers who are perhaps on the lookout for unusual information, and who might, therefore, be prepared to negotiate with the database authors directly.•Databases that are 'live' and curated must be held as superior to those that are static and unsupported.•Databases that are reported in a peer-reviewed scientific publication must likewise be held as superior to those that are undocumented.•Databases should ideally embody a range of data, including not just chemical structure data but also information on TCM usage, toxicology data, known or predicted target(s), *etc*. It is also to be preferred that the database cater for complex Boolean searches, allowing, for example, for a search for all compounds based a given natural product scaffold found in plants with a specific TCM usage.•From a practical point of view it is important to consider the 'platform' required by the database (that is, whether it can be mounted and used on computers running UNIX, or Windows, *etc*.). For intensive use, a CD/DVD version of a database is much preferable to a database accessed online (*via* the internet).•It is important to distinguish between databases where users can output a list or batch file of chemical structures from a search, and those where this is not possible. It is often the case, for example, particularly with commercial databases, that structures have to be downloaded individually, and this must be regarded as a significant limitation/deficiency.•The nature of the available chemical data held within the database is crucial to consider since this will impose limitations on the type(s) of database search and/or the type(s) of analysis that can be performed. It is important to discriminate between those databases that hold only 2D chemical structure data, those that hold 3D data on single conformers, and those that hold 3D data on multiple conformers. It is also important to discriminate those databases in which compound stereochemistry is unequivocally defined and those where stereochemistry is unspecified.

4. Evaluation criteria for CHM databases {#sec0020}
========================================

With due consideration of all the points noted above, the WP4 *in-silico* work group formulated a set of quality evaluation criteria/content and functionality check list for CHM databases The check list is shown in [Table 3](#tbl0015){ref-type="table"} , and feature criteria relating to the database content (C1--C11), the versatility of Boolean searches that are catered for (C12--C14), the nature of the allowed chemical structure output (C15--C16), and the availability of associated reports in peer-reviewed publications (C17). These various features might be used (a) in defining the content to be acquired in creation of a new CHM database, and (b) as a means for users to judge the utility of an existing CHM database. The database features deemed (by the authors) to be of greatest importance include:•those relating to content -- particularly in terms of the chemical structure data held (C1--C11);•the versatility of Boolean searches that are catered for -- the ideal being that searches involving multiple search fields are allowed, one of which is preferably a molecular structure based search field (C12--C14);•the nature of the allowed chemical structure output -- the ideal being that multiple chemical structures can be output, each in 3D format (C15--C16). Table 3Quality evaluation criteria for CHM databases.Evaluation criteriaDescription of criteriaC1Contains information on CHM usage?C2Contains botanical information of plants used in CHM?C3Contains toxicological data on CHM phytochemicals?C4Contains (known) biological activity data on CHM phytochemicals?C5Contains (predicted) biological activity data on CHM phytochemicals?C6Contains chemical structure data on CHM phytochemicals?C7Contains 2D structures of CHM phytochemicals?C8Contains 3D structures of CHM phytochemicals?C9Contains data on the molecular mechanism(s) of CHM phytochemicals?C10Data on \>1000 unique CHM phytochemicalsC11Database is live, curated and updated?C12Database can be queried by chemical structure?C13Searches with ≥2 search fields possible?C14Searches can be performed using combinations of search fields?C15Chemical structure(s) can be output in 1D (as SMILES strings)?Chemical structure(s) can be output in 2D?Chemical structure(s) can be output in 3D (as single conformers)?Chemical structure(s) can be output in 3D (as conformer libraries)?C16Facility for (batch) output of multiple chemical structuresC17Database is reported in an article in a peer reviewed journal

In view of the fact that several of the databases catalogued in [Table 1](#tbl0005){ref-type="table"} were not available for evaluation by the WP4 *in-silico* work group, it was deemed inappropriate to present any evaluation scores for the databases. Instead, the databases were simply grouped (without ranking) according to their content. Those grouped at the top of [Table 1](#tbl0005){ref-type="table"} are those considered most useful for *in-silico* studies of CHM -- in that they contain botanical, TCM and phytochemical data, including chemical structures. The databases listed in the second group are those that contain only TCM data, while those grouped last include only non-specific botanical and phytochemical information.

The majority of the databases listed in [Table 1](#tbl0005){ref-type="table"}, [Table 2](#tbl0010){ref-type="table"} do not contain information relating to the toxicology of TCM, principally because the commonly used endpoints such as LD~50~ (either for individual constituents or for herbal extracts) are of limited value in understanding the possible side effects of herbs, particularly those that arise through long term use. While Chinese medicine has always paid close attention to this sort of information, the only English-language toxicological database available is that reported by Bensoussan et al.

5. Types of software for use in computational studies of CHM {#sec0025}
============================================================

As for the review of databases (above), examples of software tools relevant to computational studies of CHM were catalogued using the knowledge and expertise of individual WP4 members together with information presented in the review by [@bib0110].

Several categories of software were deemed of relevance in CHM research. Those of use for virtual screening and/or the identification of potential mechanisms of action of CHM constituents were identified as:

**Ligand based screening programs** -- *Pre-requisite(s) for use*: knowledge of compounds with known activity; *use*: to identify putatively active compounds; *tools available*: classification/regression trees (including Random Forest), linear discriminant analysis, artificial neural networks, support vector machines.

**Pharmacophore programs** -- Can be either ligand-based (LB), or target-based (TB) (the latter being superior/preferable); *pre-requisite(s) for use*: 3D structures of known ligands to chosen targets (LB), or known 3D structures of target protein(s), and ideally known 3D structure(s) of known complex(es)) (TB); *use*: to identify putative active compounds; *programs available*: LigandScout ([@bib0360]), Schrödinger\'s Phase program ([@bib0080]) and Accelrys\'s Discovery Studio^®^ Catalyst.

**Docking programs** -- *Pre-requisites for use*: known 3D structure(s) of target proteins; *use*: to 'dock' potential small molecule ligands into protein active sites, optimising their topographical and chemical complementarity, and scoring their interaction. *Programs available*: FlexX ([@bib0260]), Gold ([@bib0190]), Dock ([@bib0300]), Glide ([@bib0165]), MolDock ([@bib0315]), AutoDock ([@bib0155]) and LigandFit ([@bib0320]).

Other relevant types of software tool were identified as:

**Pattern recognition software** -- *Use*: post-screening analyses (involving dimensionality reduction); *algorithms employed*: principle components analysis, multi-dimensional scaling, self-organising maps, and various forms of cluster analysis.

**Proteomics and/or genomics data visualisation and analysis tools** -- *Use:* application specific programs for statistical processing and visualisation of data output from DNA micro-array experiments, MS proteomics experiments, *etc*.

6. Factors for consideration in the choice of *in-silico* tools used in the study of CHM {#sec0030}
========================================================================================

In consideration of the *in-silico* tools that are readily available for use in CHM research, and the factors that might mitigate against their productive application in such research it should be noted that although the majority of tools are readily available and, for the most part, easy to operate, they are *not* suitable for those lacking the appropriate computing background. *In-silico* tools should ideally *not*, therefore, be used by non-specialists, since almost everyone can obtain an output from a computational program, but -- if not carefully produced/checked -- the output obtained could be meaningless. That said, manuals/handbooks should of course be available and should be exhaustive. *In silico* approaches and tools that facilitate and complement molecular biology studies constitute a fast moving research area. Direct interaction with experts from that area thus provide the best option for CHM experimentalists to maximise the value of *in-silico* predictions.

In assessing the utility of the various *in-silico* tools available for the study of CHM, the hardware platform is relevant, since high throughput screening approaches require a very efficient use of RAM and a stable operating system, and UNIX/MacOSX/Linux operating systems may be more suitable in this regard than Windows -- *albeit* that these are perhaps not as intuitive to set up and use as those implemented under Windows. In addition, it should be noted that the utility of web-based resources -- although in many ways very convenient -- is critically dependent on their availability.

It is not necessary that the algorithms to be used have been validated specifically for use in CHM research; and users should count it sufficient that the methods they propose to use have been validated on other data sets that are analogous to those to be investigated in the CHM studies. That said, it must also be noted that *in-silico* studies of natural products may not necessarily be conducted in quite the same way as those focused on synthetic chemical libraries -- given that the two classes of compound have rather different profiles of chemical properties ([@bib0125]).

7. Reports of target-oriented *in-silico* screening of bioactive material in CHM {#sec0035}
================================================================================

The following sections present a précis of the research reported over the period 2000--2010 wherein *in-silico* methods have been used in studies of the bioactive materials in CHM.

7.1. Virtual screening of Chinese herbs for drug discovery {#sec0040}
----------------------------------------------------------

Several studies dealing with the virtual screening (VS) of CHM constituents, most of which have been published within the last five years, have sought to employ various computational methods to identify potential ligands for protein targets of pharmacological/therapeutic interest. The screening techniques employed include pharmacophore search, molecular docking, and screening by means of chemical descriptors and fingerprints.

There are several cases reported in which compounds found in Chinese herbs have been identified as likely inhibitors of specific enzymes or receptors, and these predicted activities have subsequently been confirmed experimentally. (Such studies are clearly of greater interest than those where the *in-silico* predictions are not subsequently tested by experiment.)

It is particularly of interest to note here that for several of the reported studies significant information leading to the selection of appropriate plant material was derived from a consideration of the plants' use(s) in TCM -- thus testifying to the importance of ethnopharmacological data in VS studies.

Molecular docking studies have shown that sieboldigenin binds to the active site of soybean lipoxygenase (SLOX), and this compound was later found to inhibit SLOX with an IC~50~ of 38 μM, as well as reducing carageenan-induced paw oedema ([@bib0200]). Sieboldigenin is a spirostane sterol found in various species of *Smilax* including *Smilax glabra* (tufuling) which is used in TCM as a 'heat clearing' herb, employed largely for arthritic joint pain and skin disease.

In like manner, leucovorin was discovered as a potential anti-HIV agent by screening Chinese natural products using a molecular fingerprint based on the HIV protease inhibitor, saquinavir. Molecular dynamics studies subsequently confirmed the favourable binding of this compound to the protease active site ([@bib0145]).

Combined molecular fingerprint studies and docking were also responsible for the discovery of aurantiamide acetate, from *Artemisia annua* (qinghao), as an inhibitor of severe acute respiratory syndrome coronavirus main proteinase (SARS-CoVM^pro^; [@bib0325]).

In a search for ways to prevent surface biofilm formation, [@bib0385] performed VS studies of quorum sensing inhibitors of *Pseudomonas aeruginosa*. Fifty-one TCM compounds with known antibacterial activity were docked into the active site of the transcription activation factor TraR. *In vitro* screening of eight of the high scoring compounds subsequently showed that *Pseudomonas aeruginosa* growth was effectively inhibited by baicalein and that this compound acted synergistically with ampicillin.

Rollinger et al. used protein-based pharmacophores to screen for natural product inhibitors of acetylcholinesterase (AChE) and cyclooxygenase (COX). By this means they identified scopoletin as a potential AChE inhibitor and sanggenons as a potential COX inhibitor, and these predictions were then proved correct through *in vitro* studies ([@bib0265], [@bib0270]).

In other VS studies of CHM consitituents the screening was either carried out without reference to TCM usage or else it afforded predictions of potential ligands which were not then substantiated experimentally.

[@bib0250] selected three Chinese herbal constituents which were identified as potential aromatase inhibitors by VS based on molecular descriptors, using known phytochemical inhibitors in training, and then docked each of these into the active site of human aromatase. The three compounds studied were the flavonoids myricetin, liquiritigenin and gossypetin. Liquiritigenin was shown to have a lowest binding energy. Subsequent *in vitro* experiments confirmed these *in-silico* predictions, with liquiritigenin showing the highest potency -- exhibiting an IC~50~ of 0.34 μM and thus presenting a 10-fold increase in inhibitory activity over the first generation inhibitor, aminoglutethimide.

Guided by the TCM use of *Epimedium* spp. as tonics for 'yang invigoration', Chen et al. sought to identify constituents of these herbs which might mimic the phosphodiesterase 5 (PDE5) inhibitory effect of sildenafil ([@bib0050]). They used pharmacophores, docking and QSAR methods. Several potential inhibitors were identified and some of these -- similar in structure to ES-03b -- showed docking scores which were comparable to that shown by another known PDE5 inhibitor taladafil ([@bib0050]).

Three similar studies have been reported involving *in-silico* screening of Chinese herbs for compounds active against various kinases that present as targets for cancer therapy -- these being the aurora-A kinase, polo-like kinases and KDR kinase ([@bib0375], [@bib0070], [@bib0335]). In all three studies, a similar methodology was employed, using pharmacophores derived from known inhibitors which were used to screen the CNPD ([@bib0290]) (in the case of the aurora-A and polo-like kinase studies) and the TCMD ([@bib0255]) (for the KDR kinase study). The various hits obtained were then filtered using the Lipinski rules, regression analysis predictions of IC~50~, and molecular docking to relevant protein targets. In the case of the KDR kinase, a pterocarpan glucoside was identified as a hit from the TCMD, and this was found by experiment to have a dissociation constant of 30 μM.

7.2. Searching for multi-target ligands in Chinese herbs {#sec0045}
--------------------------------------------------------

Virtual screening studies have also been performed in the search for single phytochemicals with the potential to inhibit a variety of functionally/pathologically related targets, and also in searches for 'cocktails' of ligands, each of which is predicted to inhibit one of the targets in a series of (pathologically related) targets of interest.

[@bib0180] have shown that several constituents of plants used in the Chinese formula *Xuefu zhuyu tang* could present as inhibitors of targets relevant to the treatment of cardiovascular disease. 'Drug-like' compounds with acceptable ADME profiles were first identified by Lipinski filtering, and these were then docked to a number of targets with known significance in cardiovascular disease, including renin, angiotensin-converting enzyme (ACE), VEGFR, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) and P-glycoprotein (Pgp). A total of 283 compounds were obtained as possible inhibitors of all the selected protein targets. Out of the 11 herbs studied, the majority were identified as possible inhibitors of more than one target. Moreover, 10 of the herbs were shown to possess constituents with the potential to inhibit two or more targets, and 50% of these showed the potential to inhibit five targets.

[@bib0100] have used multiple decision trees to fish for compounds in Chinese herbs on the basis of structural similarity to known phytochemical inhibitors of targets involved in several disease processes, including inflammation, HIV and diabetes; they used Random Forest models to discriminate phytochemical inhibitors from 8000+ compounds found in 240 herbs. Target compounds that could not be distinguished from the known inhibitors for a given target on the basis of three different RF models (each employing a different set of molecular descriptors), were flagged as potential inhibitors of that target. Despite stringent selection criteria, around 62% of the plant species were hit at least once, with 50% of these predicted to have constituents active against two or more targets. Literature searches performed to corroborate these predictions, subsequently showed that 29% of the predicted classes within these herbs were supported by recent data, with ∼80% of publications providing new information distinct from that used in constructing the RF models.

The same research team later reported protein-based screening studies ([@bib0105]), employing multiple PDB ligand--receptor complexes, to identify possible ligands four major anti-inflammatory targets -- COX, p38 MAP kinase (p38 MAPK), c-Jun terminal NH~2~ kinase (JNK), and phosphodiesterase 4 (PDE4). A conformational database of Chinese herbal constituents was first screened using LigandScout pharmacophores (derived through analyses of ∼60 PDB entries). Resulting hits were subsequently docked into the relevant target proteins, and the docking scores compared against the median binding energy for the crystal ligands for that target. Analysis of the cumulative scores for compounds from distinct phytochemical classes within each herb led to the identification of the 100 plants most likely to yield mimics comparable in potency to the known PDB ligands. Further analysis revealed that the Chinese formulas in which these herbs were commonly employed, are very often used in the treatment of inflammatory conditions.

7.3. Inverse docking and target fishing {#sec0050}
---------------------------------------

Inverse docking and target fishing are *in-silico* screening techniques that are used to identify protein targets *ab initio*. These techniques can thus be viewed as particularly pertinent in studies of phytochemicals. Indeed, two of the computer programs available have been specifically developed Chinese medicine in mind, to aid in elucidating the targets of TCM constituents. The first of these, INVDOCK ([@bib0040]), is similar as regards docking methodology to Kuntz\'s DOCK program ([@bib0300]); it makes use of a database of protein cavities derived from PDB entries, and query compounds are tested for fit against some or all of these cavities to identify potential targets. The algorithm uses a shape matching alignment of the query compound to each protein cavity, with torsion optimisation and energy minimisation using the AMBER force field then employed to refine the fit. Protein cavities are defined using overlapping spheres following the approach of Kuntz et al. ([@bib0300]), and the database now holds ∼9000 entries. Validation of the methodology, using phytochemicals with known targets (including ginsenoside Rg1, baicalin, quercetin, emodin, catchin and allicin), identified ∼50% of the targets for which experimental data exist ([@bib0055], [@bib0060]). INVDOCK has also been used to identify possible targets of the cytotoxic compound ganoderic acid D from the Chinese fungus *Ganoderma lucidum* (lingzhi), following investigation of its effects on expression of 21 different proteins. The results obtained suggest that it might bind eight of these receptors directly ([@bib0380]).

TarFisDock ([@bib0225]) is another inverse docking program, and makes use of a similar methodology to INVDOCK. This program uses a protein database constructed from the PDB (with each entry comprising residues within 6.5 Å of a known ligand), with the active site defined by spheres as in INVDOCK. The docking of query compounds against the database sites is again based on Kuntz\'s DOCK algorithm. TarFisDock (<http://www.dddc.ac.cn/tarfisdock/>) is designed for use with the PDTD ([@bib0150]) and currently holds over 1100 entries covering 830 known or potential drug targets, each target being linked to information on biological function and disease. Users can access the program *via* the internet, with query compounds uploaded, and the database then searched for candidate targets *via* a web interface available at <http://www.dddc.ac.cn/pdtd/>. Successful applications of the program reported to date include the identification of a *Helicobacter pylori* target for the natural product N-*trans*-caffeoyltyramine in the enzyme peptide deformylase -- this compound, and one if its derivatives, subsequently being shown to be potent inhibitors of the enzyme with IC~50~ values of 10.8 and 1.25 μM, respectively ([@bib0030]).

Greenpharma\'s 'reverse pharmacognosy' represents another inverse docking approach ([@bib0085]), very similar to INVDOCK and TarFisDock, but differing in its use of an in-house database of ethnopharmacological data. Where pharmacognosy seeks to identify bioactive compounds from plants based on extraction and assay, *reverse* pharmacognosy seeks to screen targets and diseases from individual compounds. In part this is achieved through use of compound and target databases linked by the docking program *Selnergy* -- the use of which successfully identified ɛ-viniferin as an inhibitor of phosphodiesterase 4 (ɛ-viniferin being a stilbene found in *Sophora* spp. that are commonly used in TCM).

An alternative, related strategy used in identifying targets of phytochemical involves the screening of query compounds against pharmacophore models of PDB ligands. Such screening is significantly faster than molecular docking, and thus provides a rapid means to filter out compounds that are not direct mimics of the ligands from which the pharmacophore model is generated. This approach does have the drawback, however, that compounds that might find alternative modes of binding to the selected protein targets will not be identified as hits. The first use of this type of PDB-based pharmacophore method for target fishing for plant constituents was reported by [@bib0275]. In this study, 16 constituents of *Ruta graveolens* were screened against a database containing 2208 pharmacophores. *In vitro* screening against three targets -- AChE, HRV coat protein and cannabinoid receptor type-2 (CB~2~) -- showed a close degree of congruity between the best hits and their respective IC~50~ values.

7.4. *In-silico* tools for proteomics, genomics and metabonomics data visualisation and analysis {#sec0055}
------------------------------------------------------------------------------------------------

The advent of information rich "omic" techniques has provided powerful new research tools for use in the study of CHM. Using genomic, proteomic or metabonomic analysis, it has become possible to examine simultaneous molecular effects that result when using chemical mixtures as in CHM, affording new opportunities to study biological effects holistically, rather than by following the classical reductionistic approach -- a new vision which goes beyond single molecule pharmacology and target specificity, embracing the entire equilibrium of a biological system undergoing simultaneous perturbations. Such an approach can be considered more feasible to investigate the effects of multichemical mixtures on a plurality of biological targets, as in CHM formulae (for a review see [@bib0415]).

Using such a strategy a multitude of experimental data can be obtained that need to be handled both in terms of multichemical identification and pathophysiological correlations. With the help of bio-informatics, specific software and databases have been developed in order to exploit the large amount of raw data derived from omics techniques and allow correlation of the multiple components of a given phytocomplex with its biological effects ([@bib0330], [@bib0410]). This systems biology approach thus integrates powerful information rich technologies, computational tools and knowledge bases, making it possible to establish links between molecular patterns, biological functions and a wide range of human diseases and pharmacological interventions ([@bib0005]). In particular, high-throughput omics techniques require several bioinformatics and knowledge-assembly tools for data processing, analysis, integration and interpretation using a top-down system biology approach ([@bib0245]).

When using omics techniques, raw data are produced mostly from microarrays and mass spectrometry or NMR, depending on the technique used, and subsequent to data processing -- which often needs multivariate analysis -- sets of qualitative and quantitative data are obtained indicating patterns of induced molecular perturbations. *In-silico* tools can be used to assist in molecular identification, and databases as well as specific search software are available to assist in this task. These include the METLIN and MassBank databases for metabolomics ([@bib0280], [@bib0365], [@bib0175]), and human protein and peptide databases for proteomics ([@bib0065], [@bib0210], [@bib0075], [@bib0330], [@bib0410]).

Following analysis, the affected molecular networks can be identified and the observed perturbations correlated to a given pharmacotoxicological effect. This last correlation step is of utmost importance in order to exploit the full potential of information rich data resulting from the application of omics techniques. Several databases have been made available that can be used for guided analysis, while others can be applied to untargeted and genome-wide or metabolome-wide association studies ([@bib0305], [@bib0025]). These databases allow data mining, integrated correlations, and modelling of biochemical pathways, thus providing a platform of translational medicine that can also be used for CHM research ([@bib0400]). Molecular databases can be thus used to identify unknown metabolites or peptides, to identify structure from known elemental composition, or to determine the biological function of a specific molecule.

The catalogue of databases and software developed for genome-scale metabolic reconstructions is ever-increasing, and many of these utilities are freely available for academic use. The databases and software that are currently available have been extensively reviewed elsewhere ([@bib0215], [@bib0130], [@bib0195]), and the following section provides just a few selected examples.•The *Human Metabolome Database* (HMDB) is considered the most complete bioinformatics and chemoinformatics medical information database ([@bib0215]) with more than 6800 metabolite entries; it is fully searchable with tools for viewing, sorting metabolites and pathways, and provides customised, clickable metabolic maps, as well as disease information ([@bib0355]).•BiGG, *Biochemical Genetic and Genomic knowledge base*, is a metabolic reconstruction of human metabolism using both genetics and literature-based data to assess whether a reaction is present, providing confidence level data and Boolean relationships between genes, proteins and reactions ([@bib0285]).•The *Small Molecule Pathway Database* (SMPDB) is an interactive, visual database containing a limited number of small-molecule pathways found in humans, most of which cannot be found in any other pathway database. The SMPDB is used in metabolomics, transcriptomics and proteomics studies ([@bib0135]).•*Genomics Portals* provides a database of human, mouse, and rat genomics data with basic analytical visualisation tools ([@bib0295]).•Examples of proteomic databases include GPDE, *Griss Proteomics Database Engine*, PRIDE, *Proteomics IDEntifications database*, and *PeptideAtlas* ([@bib0140]).•Some databases are dedicated to specific fields of study. For example, T3TB, the Toxin and Toxin-Target Database, provides descriptions, mechanisms of action, and information on toxins and toxin-targets ([@bib0230]). CEBS, Chemical Effects in Biological Systems, is an integrated public repository focused on toxicogenomics, integrating data describing histopathological and biological measures with microarray and proteomics data ([@bib0345]).

Even though the introduction of omics techniques in CHM research is relatively recent and is not yet widely disseminated among scientists in the field, meaningful examples of the application of a systems biology approach can be found in the current literature, and the results are suggestive of a great potential for application of omics and related bioinformatic techniques in the study of both Chinese syndromes and phytocomplexes from traditional Chinese medicine.

The "Connectivity Map" (CMAP) has been successfully used to examine the biological effects of Chinese formulae. CMAP is a database used for the identification of functional connections between drugs, genes and diseases ([@bib0220]). Using gene expression microarrays it was possible to compare the gene expression signatures of MCF-7 cells treated with the Chinese medicine formulae Si-Wu-Tang, with those of 1309 compounds present in the CMAP database, thus allowing the matching of the formula-induced pattern with that of estradiol-treated cells, suggesting a phytoestrogenic effect ([@bib0350]).

Using a similar approach, Cheng et al. tested the effects of 15 different Chinese herbal formulae on mouse kidney and liver, analysing DNA expression on microarrays. The molecular signatures of the formulae were compared with those from drugs, or disease states in three different databases. In addition to using CMAP to compare the formulae-regulated genes with those of known drugs, the *Genetic Association Database* was used for comparing with gene expression patterns from disease states ([@bib0010]) and the *Environment, Drugs and Gene Expression* (EDGE) database to compare with the effect patterns resulting from exposures to chemicals ([@bib0170]). The results showed numerous matches allowing predictions on both the pharmacological effects and the toxicological potential of the formulae ([@bib0400]).

Transcriptomics was also used to analyse the effects of San-Huang-Xie-Xin-Tang and its herbal components on the HepG2 human hepatoma cell line. Using the Molecular Signature Database website, TIGR Multiexperiment Viewer and BiblioSphere Pathway Edition software, it was found that the formula displayed an antiproliferation pattern *via* the p53 pathway, signalling an effect that was also shown to be attributable primarily to a single herbal component ([@bib0395]).

Pro-apoptotic and pro-inflammatory pathways were shown to be activated when using the Chinese herbal formula PHY906 on tumour bearing mice. In this case, gene functions were congregated into pathways and networks using Ingenuity Pathways Analysis (IPA) ([@bib0330], [@bib0410]).

IPA was also used to analyse microarrays for gene expression in mice fed with *Ginkgo biloba*. The results showed alterations in several pathways, suggesting implications of both pharmacotoxicological and pharmacokinetic interest when using *Ginkgo biloba* ([@bib0160]).

A metabonomic study was performed analysing urine collected from rats fed with Morning Glory (*Pharbitis purpurea*) seeds, to study the nephrotoxicity induced by this plant -- commonly used in TCM. Urine was analysed by ultra-performance liquid chromatography/mass spectrometry (UPLC/MS) and mass spectra were interpreted with the aid of biochemical databases, such as KEGG, METLIN, and SciFinder and eight endogenous metabolites as biomarkers were found to be significantly changed in the urine ([@bib0240]).

The 'Kidney-Yang Deficiency syndrome' induced by high doses of hydrocortisone and the therapeutic effects of the dried rhizome of *Drynaria fortunei*, traditionally used for treating the syndrome, were studied using a metabonomic approach. Urine samples were analysed with UPLC/MS and identification of potential markers, was sought using the HMDB, METLIN, Massbank, PubChem and KEGG databases. The work provided indications on biochemical pathways which correlated with the syndrome-related dysfunctions in energy metabolism as well as the efficacy of the *Drynaria* treatment ([@bib0235]).

A proteomics analytical approach was used to study the effect of *Salvia miltiorrhiza* on vascular atherosclerotic lesions, using an *in vitro* smooth muscle cell model. Two-dimensional electrophoresis coupled with mass spectrometry was used to analyse proteins under oxidative stress and treatment with the herbal extract. The MetaCore software was then used to investigate the biological pathways involved and it was found that *Salvia miltiorrhiza* exerts its protective effect by acting on the scavenging of ROS and subsequent modulation of protein carbonylation to inhibit cell proliferation ([@bib0185]).

A large amount of experimental data generated by high-throughput techniques is available through various public repositories. Knowledge about transcriptional regulation, molecular interaction networks and metabolic pathways is rapidly expanding thanks to the innovative system biology approach, information rich omics technology and computer assisted analysis. In this rapidly evolving context the experimental study of multiple target, multichemical pharmacologic effects with phytocomplexes as in CHM, can greatly benefit from this new holistic scientific vision.

8. Conclusions {#sec0060}
==============

*In-silico* tools are best applied in CHM research as a means: to seek out potential mechanisms of action of their constituents; to identify putative new leads for drugs; and to summarise and/or visualise the complex patterns embedded within the output generated through associated 'omics studies. Given the complexity of CHM, and the ensuing difficulties in performance of the relevant experimental work, *in-silico* studies clearly offer an economical and efficient way of exploring the problem landscape and they can thus aid in the formulation of appropriate hypotheses for subsequent testing in (*in vitro* and/or *in vivo*) laboratory studies.

The utility and choice of *in-silico* screening tools are dependent on the reason(s) for their use and/or the nature of the output to be generated. The knowledge of the computational specialist is essential in guiding decisions made here, and it is imperative that the tools should be applied in CHM research through close collaboration between computational specialists and CHM experimentalists.
